delta4.ai: Accelerating Drug Discovery with AI-Powered Indication Expansion

delta4.ai is a cutting-edge TechBio company revolutionizing pharmaceutical research through its proprietary in-silico AI platform, Hyper-C. Specializing in drug repurposing and indication expansion, the platform leverages big data, multi-omics datasets, and advanced computational biology to uncover new therapeutic uses for existing drugs with known safety profiles. By combining AI-driven molecular modeling with expert scientific insight, delta4.ai significantly reduces development time—claiming up to 70 man-years saved—and enhances the accuracy and efficiency of drug discovery. Its multidisciplinary team of computational biologists, medical experts, and AI scientists drives innovation in rare diseases and complex conditions like Focal Segmental Glomerulosclerosis, ADPKD, and Long Covid. With proven success in EU-funded projects and strong partnerships, delta4.ai delivers transparent, scientifically grounded hypotheses and supports regulatory and clinical trial planning.

Key Features:

• Hyper-C AI Platform: Proprietary in-silico system for AI-powered drug discovery and indication expansion.
• Drug Repurposing & Indication Expansion: Identifies new therapeutic uses for drugs with established safety profiles.
• Multi-Omics Data Integration: Combines genomic, proteomic, and metabolomic datasets from 20+ sources.
• Network-Based Molecular Modeling: Builds and refines disease and drug mechanism models using network alignment algorithms.
• Mechanism of Action Hypotheses: Provides clear, interpretable scientific rationales—avoiding the 'black box' issue.
• Target Identification & Ranking: Pinpoints disease-modifying drug targets with high precision.
• Biomarker Discovery: Proposes prognostic and predictive protein biomarkers.
• Side Effect & Drug Effect Insights: Uses AI to analyze drug impacts and potential adverse effects.
• Regulatory & Clinical Trial Support: Offers guidance for trial design and intellectual property strategy.
• Pipeline Services: Full-service development programs advancing preclinical and clinical candidates.
• EU-Funded Research Projects: Active in Horizon 2020 and Horizon Europe initiatives like IMPROVE-PD and PROMOTE.
• Collaborative Ecosystem: Member of Scientist.com for streamlined research partnerships.

Pricing: delta4.ai operates on a custom, project-based pricing model tailored to clients’ needs, offering flexible engagement options for pharmaceutical and biotech partners. While no public pricing tiers are listed, the company provides a trial-like consultation process to assess feasibility and value.

Conclusion: delta4.ai stands at the forefront of AI-driven pharmaceutical innovation, delivering transparent, data-rich, and scientifically validated drug discovery solutions that accelerate development timelines and unlock new treatments for challenging diseases—making it an indispensable partner for forward-thinking biotech and pharma organizations.